S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
LON:PRTC

PureTech Health Share Forecast, Price & News

GBX 418.68
-6.83 (-1.60 %)
(As of 03/5/2021 05:05 PM ET)
Add
Compare
Today's Range
394
Now: GBX 418.68
423
50-Day Range
368
MA: GBX 394.18
425.50
52-Week Range
198.50
Now: GBX 418.68
447.66
Volume213,266 shs
Average Volume241,447 shs
Market Capitalization£1.20 billion
P/E Ratio2.64
Dividend YieldN/A
BetaN/A
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PureTech Health logo

Headlines

Do Institutions Own PureTech Health plc (LON:PRTC) Shares?
February 22, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-617-4822333
Employees300
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£12.26 million
Cash FlowGBX 119.59 per share
Book ValueGBX 274.50 per share

Profitability

Miscellaneous

Market Cap£1.20 billion
Next Earnings Date4/5/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.51 out of 5 stars

Analyst Opinion: 2.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
GBX 418.68
-6.83 (-1.60 %)
(As of 03/5/2021 05:05 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PureTech Health (LON:PRTC) Frequently Asked Questions

Is PureTech Health a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PureTech Health in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PureTech Health stock.
View analyst ratings for PureTech Health
or view top-rated stocks.

What stocks does MarketBeat like better than PureTech Health?

Wall Street analysts have given PureTech Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PureTech Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PureTech Health's next earnings date?

PureTech Health is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for PureTech Health
.

How has PureTech Health's stock price been impacted by Coronavirus?

PureTech Health's stock was trading at GBX 274 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTC stock has increased by 52.8% and is now trading at GBX 418.68.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PRTC?

4 analysts have issued 1-year price objectives for PureTech Health's stock. Their forecasts range from GBX 475 to GBX 490. On average, they anticipate PureTech Health's share price to reach GBX 481.25 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for PureTech Health
or view top-rated stocks among Wall Street analysts.

Who are PureTech Health's key executives?

PureTech Health's management team includes the following people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 47)
  • Dr. Bennett M. Shapiro, Co-Founder & Non-Exec. Director (Age 78)
  • Dr. Robert S. Langer Jr., Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 69)
  • Mr. Stephen M. Muniz J.D., COO, Exec. VP of Legal & Operations, Sec. and Exec. Director (Age 48)
  • Dr. Bharatt M. Chowrira, Pres and Chief of Bus. & Strategy (Age 53)

Who are some of PureTech Health's key competitors?

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PureTech Health investors own include Nemaska Lithium (NMX), Yamana Gold (YRI), Asanko Gold (AKG), Arotech (ARTX), The Boeing (BA), Baozun (BZUN), Chaarat Gold Holdings Limited (CGH.L) (CGH), Eldorado Gold (ELD), CarMax (KMX) and Knowles (KN).

What is PureTech Health's stock symbol?

PureTech Health trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

How do I buy shares of PureTech Health?

Shares of PRTC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately GBX 418.68.

How much money does PureTech Health make?

PureTech Health has a market capitalization of £1.20 billion and generates £12.26 million in revenue each year.

How many employees does PureTech Health have?

PureTech Health employs 300 workers across the globe.

What is PureTech Health's official website?

The official website for PureTech Health is puretechhealth.com.

Where are PureTech Health's headquarters?

PureTech Health is headquartered at 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States.

How can I contact PureTech Health?

PureTech Health's mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The company can be reached via phone at +1-617-4822333.


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.